<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02969642</url>
  </required_header>
  <id_info>
    <org_study_id>AP 1001</org_study_id>
    <nct_id>NCT02969642</nct_id>
  </id_info>
  <brief_title>Study of Low-level Laser Therapy in the Acute Treatment of Migraine</brief_title>
  <official_title>A Single-center, Sham-controlled, Single Attack Study of Laser Therapy to the Sphenopalatine Ganglion (SPG) in the Acute Treatment of Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The San Francisco Clinical Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The San Francisco Clinical Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the treatment of migraine pain using low energy laser light to quench&#xD;
      migraine signals issuing from the sphenopalatine ganglion (SPG).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blinded, two arm study, comprising a sham laser and a treatment laser. The&#xD;
      sham laser emits approximately 1/1000 the energy of the treatment laser.&#xD;
&#xD;
      It is presumed that pain relief from the treatment laser is achieved by exhausting the&#xD;
      release of neurotransmitters from the SPG following laser stimulation. Subjects will be&#xD;
      treated and subsequently queried at time intervals for their self-assessment of pain score&#xD;
      (VAS). The time intervals include queries at 5 minutes through 2 hours post treatment.&#xD;
      Subjects will be further contacted 24 hours and one month post treatment. Adverse events will&#xD;
      be monitored and recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences between treatment groups in pain free rates at 2 hours post treatment.</measure>
    <time_frame>2 hours post treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Migraine Headache</condition>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham low energy laser using approximately 1/1000 th energy of treatment laser.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment laser.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Argus Migraine Treatment device</intervention_name>
    <description>treatment of Migraines targeting Sphenopalatine ganglion</description>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>low energy laser therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  male or female&#xD;
&#xD;
          -  aged 18 or older;&#xD;
&#xD;
          -  subject diagnosed with migraine according to The International Classification of&#xD;
             Headache Disorders- Version 3;&#xD;
&#xD;
          -  1-20 headache days per month;&#xD;
&#xD;
          -  history of at least moderate pain if migraine left untreated.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  headache on greater than 25 days/month on average for preceding 3 months;&#xD;
&#xD;
          -  headache on greater than 25 days in present month;&#xD;
&#xD;
          -  headache attributed to: head or neck trauma, cluster headache, specific migraine&#xD;
             variants such as basilar artery, ophthalmoplegic, hemiplegic, etc;&#xD;
&#xD;
          -  women of child bearing age not using acceptable method of contraception;&#xD;
&#xD;
          -  pregnant or nursing women;&#xD;
&#xD;
          -  history of malignancy of any organ&#xD;
&#xD;
          -  uncontrolled: hypertension, severe psychiatric disorders, or known use of narcotics,&#xD;
             analgesic or alcohol abuse;&#xD;
&#xD;
          -  light sensitivity;&#xD;
&#xD;
          -  retinal disease;&#xD;
&#xD;
          -  intranasal pathology.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>San Francisco Clinical Research Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerome Goldstein, MD</last_name>
      <phone>415-673-4600</phone>
      <email>JGoldstein@sfcrc.org</email>
    </contact>
    <investigator>
      <last_name>Jerome Goldstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>October 20, 2016</study_first_submitted>
  <study_first_submitted_qc>November 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2016</study_first_posted>
  <last_update_submitted>December 1, 2016</last_update_submitted>
  <last_update_submitted_qc>December 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

